Cargando…
Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359258/ https://www.ncbi.nlm.nih.gov/pubmed/33340199 http://dx.doi.org/10.1002/ejhf.2074 |
| _version_ | 1783737508145659904 |
|---|---|
| author | Damy, Thibaud Sultan, Marla B. Witteles, Ronald |
| author_facet | Damy, Thibaud Sultan, Marla B. Witteles, Ronald |
| author_sort | Damy, Thibaud |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8359258 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley & Sons, Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83592582021-08-17 Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’ Damy, Thibaud Sultan, Marla B. Witteles, Ronald Eur J Heart Fail Letter to the Editor John Wiley & Sons, Ltd. 2021-02-16 2021-06 /pmc/articles/PMC8359258/ /pubmed/33340199 http://dx.doi.org/10.1002/ejhf.2074 Text en © 2020 Pfizer Inc. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letter to the Editor Damy, Thibaud Sultan, Marla B. Witteles, Ronald Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’ |
| title | Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’ |
| title_full | Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’ |
| title_fullStr | Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’ |
| title_full_unstemmed | Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’ |
| title_short | Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’ |
| title_sort | reply to the letter regarding the article ‘efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (attr‐act) and long‐term extension study’ |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359258/ https://www.ncbi.nlm.nih.gov/pubmed/33340199 http://dx.doi.org/10.1002/ejhf.2074 |
| work_keys_str_mv | AT damythibaud replytotheletterregardingthearticleefficacyandsafetyoftafamidisdosesinthetafamidisintransthyretincardiomyopathyclinicaltrialattractandlongtermextensionstudy AT sultanmarlab replytotheletterregardingthearticleefficacyandsafetyoftafamidisdosesinthetafamidisintransthyretincardiomyopathyclinicaltrialattractandlongtermextensionstudy AT wittelesronald replytotheletterregardingthearticleefficacyandsafetyoftafamidisdosesinthetafamidisintransthyretincardiomyopathyclinicaltrialattractandlongtermextensionstudy |